SKYSCRAPER-04
Phase 2 Completed
172 enrolled 27 charts
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Phase 3 Completed
161 enrolled
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
Phase 1 Completed
40 enrolled 17 charts
ATEZOLACC
Phase 2 Completed
189 enrolled
AtTEnd
Phase 3 Completed
549 enrolled
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
Phase 3 Completed
574 enrolled
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Completed
12 enrolled
ATALANTE
Phase 3 Completed
614 enrolled
ACTolog
Phase 1 Completed
38 enrolled
VolATIL
Phase 2 Completed
47 enrolled
ANITA
Phase 3 Completed
417 enrolled
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
Phase 1 Completed
77 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Phase 2 Completed
25 enrolled 15 charts
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
Phase 2 Completed
122 enrolled
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Phase 2 Completed
11 enrolled 11 charts
IMagyn050
Phase 3 Completed
1,301 enrolled 22 charts
AdORN
Phase 1/2 Completed
18 enrolled 15 charts